Candida Infection Testing Market Report 2024

This Candida Infection Testing market report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The candida infection testing market size has grown strongly in recent years. It will grow from $14.78 billion in 2023 to $15.69 billion in 2024 at a compound annual growth rate (CAGR) of 6.2%. Growth during the historic period can be attributed to the increasing incidence of Candida infections, heightened awareness and diagnostics, expansion of healthcare infrastructure, a rise in hospital-acquired infections, and increased funding for research.

The candida infection testing market size is expected to see strong growth in the next few years. It will grow to $20.05 billion in 2028 at a compound annual growth rate (CAGR) of 6.3%. The growth projected for the forecast period can be linked to the emergence of new Candida strains, increased awareness of fungal infections, expanded healthcare access, an aging population, and a focus on preventive healthcare. Key trends during this period include advancements in molecular diagnostics, the integration of digital health technologies, AI, machine learning, and the adoption of personalized medicine.

The growing prevalence of yeast infections is anticipated to drive the expansion of the candida infection testing market. Yeast infections, caused by the overgrowth of the fungus Candida, commonly affect areas such as the mouth, genitals, and skin, leading to symptoms such as itching, redness, and discomfort. Factors such as imbalances in the body’s natural bacteria, weakened immune systems, and hormonal changes are key contributors to Candida overgrowth. Candida infection testing plays a crucial role in diagnosing these infections, enabling healthcare providers to confirm the presence of Candida and determine the appropriate treatment. For example, according to GOV.UK in September 2023, the rate of bloodstream infections caused by yeast in England increased to 4 per 100,000 population in 2022, reflecting a 4% rise from 2021. This upward trend in yeast infections is expected to fuel growth in the candida infection testing market.

Major players in the candida infection testing market are increasingly focusing on developing advanced technological solutions, such as fully automated PCR rapid tests for detecting Candida. These high-tech diagnostic tools utilize polymerase chain reaction (PCR) technology to provide quick and accurate detection of Candida species in clinical samples. For instance, in May 2024, Bosch Healthcare Solutions GmbH, a medical technology company based in Germany, introduced a PCR test for Candida auris detection on the Vivalytic platform. This test offers fully automated, rapid results within one hour at the point of care, significantly reducing the time required compared to traditional culture methods, which typically take one to three days in centralized laboratories. This innovation is particularly valuable for clinical settings and high-risk patients, enabling timely diagnosis and treatment of serious C. auris infections.

In February 2024, Bruker Corporation, a US-based provider of scientific instruments and analytical solutions, announced the completion of its acquisition of ELITechGroup for approximately €870 million (around $942 million) in cash. This acquisition is a strategic step for Bruker to expand its portfolio in molecular diagnostics and infectious disease testing by incorporating ELITech's innovative technologies and expertise. ELITechGroup, based in France, is a global leader in the in vitro diagnostics (IVD) industry.

Major companies operating in the candida infection testing market are Thermo Fisher Scientific Inc., Abbott Laboratories, Siemens Healthineers AG, Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Hologic Inc., bioMérieux SA, Bio-Rad Laboratories Inc., Bruker Corporation, QIAGEN N.V., Cepheid, Randox Laboratories Ltd., Meridian Bioscience Inc., DiaSorin S.p.A., Sekisui Diagnostics LLC, Enzo Biochem Inc., T2 Biosystems Inc., Aidian Oy, SafeCare LLC, CHROMagar, HK Biotek Inc., Health Testing Centers LLC, Accesa Labs LLC, Private MD Labs LLC.

North America was the largest region in the candida infection testing market in 2023. The regions covered in the candida infection testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the candida infection testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Candida infection testing involves diagnostic procedures used to detect the presence of Candida species, which are fungi that can lead to infections in different parts of the body. These tests help identify the type and severity of the Candida infection, allowing for appropriate treatment planning.

The primary types of Candida infection testing are for invasive candidiasis and candidemia. Invasive candidiasis is a serious fungal infection that occurs when Candida yeast enters the bloodstream, spreading to various organs such as the heart, brain, eyes, bones, and other tissues. Testing methods include vaginal pH tests, nucleic acid amplification testing (NAAT), and microbiome tests, applied in settings such as hospitals and laboratories.

The candida infection testing market research report is one of a series of new reports that provides candida infection testing market statistics, including candida infection testing industry global market size, regional shares, competitors with a candida infection testing market share, detailed candida infection testing market segments, market trends and opportunities, and any further data you may need to thrive in the candida infection testing industry. This candida infection testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The candida infection testing market includes revenues earned by entities by providing services such as diagnostic testing services, culture testing, consultation services, training and support, and microscopic examination. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.